Heterocyclic Scaffolds in Cardiovascular Drug Development: The Emerging Role of Pyridazine Derivatives

The therapeutic potential of various nitrogen-containing heterocyclic compounds has significantly contributed to the development of cardiotonic drugs. This article explores pyridazine-based cardiotonic agents—such as sulmazole, pimobendan, and levosimendan—which are noted for their ability to reduce both preload and afterload while exhibiting positive inotropic and vasodilatory properties. Particular emphasis is placed on the pyridazine and pyridazinone families due to their broad pharmacological activity and promising applications in the treatment of cardiovascular disorders. Beyond their cardiac effects, these compounds demonstrate a wide range of biological activities, including antibacterial, antithrombotic, antihypertensive, anti-allergic, antidiabetic, anticancer, and anti-ulcer effects. Pyridazine and pyridazinone derivatives are frequently employed in pharmaceutical development due to their versatile pharmacological profiles. While existing studies underscore their clinical importance, further laboratory research is essential to expand their therapeutic applications.